Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)

Beijing Tiantan Biological Products Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4,874	4,555	3,713	4,330	1,748	1,413
Cash & Short-Term Investments	4,874	4,555	3,713	4,330	1,748	1,413
Cash Growth	30.01%	22.68%	-14.25%	147.68%	23.69%	13.11%
Accounts Receivable	119.45	94.13	1,173	1,027	695.59	636.47
Other Receivables	53.11	39.08	28.36	22.27	16.93	22.75
Receivables	172.56	133.21	1,201	1,050	712.52	659.22
Inventory	3,138	2,844	2,332	2,144	2,172	1,949
Other Current Assets	44.83	36.53	24.87	22.27	23.64	24.32
Total Current Assets	8,229	7,569	7,271	7,546	4,656	4,046
Property, Plant & Equipment	5,124	4,886	4,055	2,631	1,997	1,560
Long-Term Investments	143.2	146.06	146.06	146.06	121.59	106.59
Goodwill	173.92	173.92	173.92	127.93	115.01	115.01
Other Intangible Assets	723.4	686.88	441.63	370.99	252.44	293.21
Long-Term Deferred Tax Assets	60.05	46.74	60.63	67.01	63.11	53.79
Long-Term Deferred Charges	474.33	470.26	552.69	362.46	174.08	61.63
Other Long-Term Assets	210.94	208.66	228.88	326.85	161.34	78.03
Total Assets	15,139	14,188	12,929	11,578	7,541	6,314
Accounts Payable	119.63	179.1	69.39	73.7	45.86	49.94
Accrued Expenses	421.94	168.69	163.21	150.02	146.85	40.17
Short-Term Debt	-	-	-	-	200.13	-
Current Portion of Long-Term Debt	-	-	112.99	108.15	126.25	-
Current Portion of Leases	13.85	17.95	10.82	16.51	-	-
Current Income Taxes Payable	126.03	61.85	73.79	44.86	36.63	40.19
Current Unearned Revenue	493.04	357.26	292.72	215.31	200.66	154.71
Other Current Liabilities	401.05	494.78	434.44	201.03	182.98	366.93
Total Current Liabilities	1,576	1,280	1,157	809.58	939.36	651.94
Long-Term Debt	-	-	253.75	366.25	474.59	400.6
Long-Term Leases	29.68	24.42	25.62	18.01	-	-
Long-Term Unearned Revenue	97.32	99.56	101.9	92.69	80.83	73.55
Long-Term Deferred Tax Liabilities	27.84	28.85	30.87	20.14	11.15	9.69
Other Long-Term Liabilities	1.24	1.24	4.1	4.1	4.1	1.26
Total Liabilities	1,732	1,434	1,574	1,311	1,510	1,137
Common Stock	1,977	1,648	1,648	1,373	1,254	1,045
Additional Paid-In Capital	2,463	2,793	2,793	3,067	274.62	274.62
Retained Earnings	5,875	5,382	4,355	3,612	2,989	2,619
Comprensive Income & Other	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1
Total Common Equity	10,316	9,823	8,795	8,052	4,518	3,939
Minority Interest	3,092	2,932	2,560	2,215	1,513	1,238
Shareholders' Equity	13,408	12,754	11,356	10,267	6,031	5,177
Total Liabilities & Equity	15,139	14,188	12,929	11,578	7,541	6,314
Total Debt	43.53	42.37	403.17	508.92	800.97	400.6
Net Cash (Debt)	4,830	4,513	3,310	3,821	947.15	1,013
Net Cash Growth	42.16%	36.34%	-13.38%	303.40%	-6.48%	-0.58%
Net Cash Per Share	2.43	2.27	1.66	1.97	0.52	0.56
Filing Date Shares Outstanding	1,977	1,977	1,977	1,977	1,806	1,806
Total Common Shares Outstanding	1,977	1,977	1,977	1,977	1,806	1,806
Working Capital	6,654	6,290	6,113	6,736	3,717	3,394
Book Value Per Share	5.22	4.97	4.45	4.07	2.50	2.18
Tangible Book Value	9,418	8,962	8,180	7,553	4,150	3,531
Tangible Book Value Per Share	4.76	4.53	4.14	3.82	2.30	1.95
Buildings	2,321	2,241	1,957	963.02	949.32	800.52
Machinery	2,262	2,218	1,996	1,258	1,177	1,082
Construction In Progress	2,259	2,044	1,532	1,623	1,030	739.97

Source: S&P Capital IQ. Standard template. Financial Sources.